Annovis raised $21.0 million through an underwritten offering to fund operations through the DUET-AD readout, giving it a stated path to that milestone. The study has not reported results, and the source gives no share terms for the offering.
That cash gives Annovis a stated path to keep operating through the key Alzheimer’s study update. The Parkinson’s study has enrolled patients, but neither update shows whether the treatment works.
Follow Annovis Bio, Inc. (ANVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ANVS